Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Registration

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

By Notice dated May 16, 2003, and published in the Federal Register on June 11, 2003, (68 FR 35006), Noramco, Inc. (formerly Noramco of Delaware, Inc.), 500 Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal and on December 4 and 26, 2002, by letters to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

DrugSchedule
Codeine-N-Oxide (9053)I
Morphine-N-Oxide (9307)I
Codeine (9050)II
Oxycodone (9143)II
Hydrocodone (9193)II
Morphine (9300)II
Thebaine (9333)II
Oxymorphone (9652)II

The firm plans to manufacture the listed controlled substances for distribution to its customers as bulk products.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Noramco, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Start Printed Page 57930Assistant Administrator, Office of Diversion control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed is granted.

Start Signature

Dated: September 17, 2003.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. 03-25409 Filed 10-6-03; 8:45 am]

BILLING CODE 4410-09-M